Trial Profile
Prospective observational study to evaluate the efficacy and safety of osimertinib by PK/PD/PGx analysis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- Acronyms NCCH-1608
- 20 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2017 New trial record